AstraZeneca
AZN
and partner
Merck
MRK
announced that the FDA extended the review period for their supplemental new drug application (“sNDA”) seeking approval for expanded use their blockbuster PARP inhibitor Lynparza in metastatic castration-resistant prostate cancer (mCRPC) indication
The FDA extended the review period by another three months to further review this sNDA submission despite the filing being accepted for priority review. Prior to the extension, a decision from the regulatory authority was expected by this year’s end. The FDA decision should now come sometime in March 2023.
The sNDA seeks label expansion for Lynparza in combination with
J&J
’s
JNJ
prostate cancer drug, Zytiga (abiraterone), and corticosteroid prednisone or prednisolone for mCRPC in patients for whom chemotherapy is not clinically indicated.
The sNDA is supported by data from the phase III study — PROpel. In the study, Lynparza plus J&J’s Zytiga and prednisone or prednisolone reduced the risk of disease progression or death by 34% versus Zytiga alone. Median radiographic progression-free survival (rPFS) was 24.8 months in the Lynparza plus Zytiga arm versus 16.6 months for Zytiga alone.
Lynparza is already approved in the U.S. as monotherapy for patients with HRR gene-mutated mCRPC who have been previously treated with J&J’s Zytiga or Pfizer’s Xtandi (enzalutamide) based on the PROfound phase III study.
This year, AstraZeneca’s shares have risen 19.7% compared with the
industry
’s 13.9% rise.
Image Source: Zacks Investment Research
AstraZeneca/Merck also submitted a regulatory filing seeking a similar label expansion for Lynparza in Europe. Last month, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion
recommending
the approval of Lynparza for the expanded use in prostate cancer. Similar regulatory filings are also being reviewed in other countries.
AstraZeneca markets Lynparza in partnership with Merck. The profit-sharing deal between AstraZeneca and Merck was inked in 2017. In addition to Lynparza, the deal included Koselugo.
Lynparza is approved for four cancer types, namely ovarian, breast, prostate and pancreatic. The PARP inhibitor is also being evaluated in an earlier-line setting for the approved cancer indications and some other cancer types.
In the first nine months of 2022, Lynparza generated product sales of $1.95 billion for AstraZeneca and alliance revenues of $825 million for Merck.
Zacks Rank & Stocks to Consider
AstraZeneca currently carries a Zacks Rank #3 (Hold).A better-ranked stock in the overall healthcare sector is
BioNTech
BNTX
which carries a Zacks Rank #2 (Buy). You can see
the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
.
In the past 30 days, estimates for BioNTech’s 2022 earnings per share have risen from $34.47 to $35.38. During the same period, the loss estimates per share for 2023 have narrowed from $16.97 to $17.53. Shares of BioNTech have lost 29.4% in the year-to-date period.
Earnings of BioNTech beat estimates in three of the last four quarters and missed the mark once, witnessing a surprise of 58.99% on average. In the last reported quarter, BNTX delivered an earnings surprise of 92.35%.
Zacks Top 10 Stocks for 2023
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2023? From inception in 2012 through November, the
Zacks Top 10 Stocks
portfolio has tripled the market, gaining an impressive +884.5% versus the S&P 500’s +287.4%.
Now our Director of Research is combing through 4,000 companies covered by the Zacks Rank to handpick the best 10 tickers to buy and hold. Don’t miss your chance to get in on these stocks when they’re released on January 3.
Be First to New Top 10 Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
